There could be a few science organisations that will work to review/replicate/prove the activity. Some of these maybe paid to do so. Further, a few BPs may pay for an investigation, especially if they have an oncology drug coming to the end of patent. A few non-profits may get involved in the investigation for better outcomes for cancer patients.
i.e. more focus and market awareness of Bisantrene, and its owner Race Oncology.
Will that reflect in the SP rising? Maybe yes, maybe no. I think once the MOA is demonstrated in trials with Cardio Protection and/or Multiple Organ Protection will we see plenty of share price activity.
At some point this data is likley to trigger some licencing or other commercial negotiations to benefit Race and its shareholders.
Good luck
RAC Price at posting:
$1.23 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)